ANR Stock Overview
Engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Anatara Lifesciences Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.056 |
| 52 Week High | AU$0.072 |
| 52 Week Low | AU$0.021 |
| Beta | 0.81 |
| 11 Month Change | -1.75% |
| 3 Month Change | 21.74% |
| 1 Year Change | n/a |
| 33 Year Change | -58.52% |
| 5 Year Change | -71.28% |
| Change since IPO | -92.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANR | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -6.7% | 3.0% | 1.2% |
| 1Y | n/a | 13.6% | 19.7% |
Return vs Industry: Insufficient data to determine how ANR performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how ANR performed against the Australian Market.
Price Volatility
| ANR volatility | |
|---|---|
| ANR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine ANR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | David Brookes | anataralifesciences.com |
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. The company offers Gastrointestinal ReProgramming, a proprietary formulation to address irritable bowel syndrome. It also provides Detach for the treatment of diarrhea disease in piglets.
Anatara Lifesciences Ltd Fundamentals Summary
| ANR fundamental statistics | |
|---|---|
| Market cap | AU$11.19m |
| Earnings (TTM) | -AU$1.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.7x
P/E RatioIs ANR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANR income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$748.91k |
| Gross Profit | -AU$748.91k |
| Other Expenses | AU$702.33k |
| Earnings | -AU$1.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0075 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANR perform over the long term?
See historical performance and comparison